Sun Pharmaceuticals has received the USFDA approval for a drug named YONSA.

YONSA is a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

In a filing to the exchanges the company stated that, YONSA in combination with methylprednisolone was filed as a New Drug Application (NDA) under the 505(b)(2) regulatory pathway and will be promoted as a branded product in the US.

Further, Abhay Gandhi, CEO-North America, Sun Pharma stated, “We are pleased to add YONSA to our growing oncology portfolio and continue to deliver on Sun Pharma’s commitment for enhanced patient access to innovative cancer therapies.”

Read EquityPandit’s Technical Analysis of Sun Pharma Outlook for the Week